✅ Suggested content. Review the technical data and compliance, adjust whatever you need and delete this line before publishing.
Retatrutide is a triple agonist peptide: it acts on the GIP, GLP-1 and glucagon receptors. It is one of the newest molecules in metabolic research. NeoPeptidos offers it as research-grade material, with ≥99% HPLC purity and exclusively for research.
Technical profile
| Product | Retatrutide |
|---|---|
| CAS | 2381089-83-2 |
| Molecular formula | C₂₂₃H₃₄₃N₄₆O₇₀ |
| Molecular weight | 4731.33 Da |
| Sequence | Triple agonista GLP-1/GIP/GCG (39 aa) |
| Purity | 99% HPLC |
| Presentation | Lyophilized vial; bacteriostatic water included |
| Use | For scientific research use only |
What is Retatrutide?
Unlike single- or dual-receptor agonists, Retatrutide is designed to activate three targets related to energy and glucose metabolism. That is why it is described as a triple agonist, and it represents a more recent line of research within incretin peptides.
Research context
Retatrutide is the subject of scientific research in the metabolic area, on the regulation of glucose and body weight in ongoing preclinical and clinical studies.
The NeoPeptidos product is research-grade material, not a clinical medicine; it includes no indications or administration schedules and is intended exclusively for researchers.
Handling and reconstitution
See the reconstitution guide and the storage guide.
Quality and traceability
≥99% purity by HPLC and batch COA. See quality control.
🔬 Updated on June 8, 2026 · Reviewed by the NeoPeptidos team · Content for research purposes (RUO).